How MKGAY
maps according to Revere
| Sector Level |
Count |
Industries
|
1 |
Sectors
|
1 |
Subsectors
|
2 |
Product/Service Groups
|
2 |
Specific product example for MKGAY
| Product Hierarchy |
|
Healthcare
|
|
Biopharmaceuticals
|
|
Immunology
|
Autoimmune Disorders
|
|
Multiple Sclerosis (MS)
|
|
Adenosine Deaminase Inhibitors
|
Company Highlights:
Market Cap.
|
n/a
|
|
Current Shares Outstnd.
|
n/a
|
| Contact Name
|
|
| Contact Phone
|
|
| City, State
|
Darmstadt,
|
| Dividends Per Common Share
|
n/a
|
| Dividend Yield
|
1.33
|
|
SI %SHOUT
|
n/a
|
|
IH % Shares Outst.
|
0.01%
|
| Number of Employees
|
n/a
|
| Revenue Per Employee
|
n/a
|
| Book Value Per Share
|
n/a
|
| 5 Year CAGR in Revenues %
|
n/a
|
| 5 Year CAGR in Earnings %
|
n/a
|
|
Asset Turnover
|
n/a
|
| Fiscal Year End
|
n/a
|
| Next Reporting Period
|
n/a
|
Business Description:
Merck is a global pharmaceutical and chemical company with sales of EUR 7.1 billion in 2007, a history that began in 1668, and a future shaped by 30,968 employees in 63 countries.Following the acquisition of the Swiss biotech firm Serono in early 2007, Merck's pharmaceuticals business comprises branded prescription drugs, e.g. for the treatment of cancer, neurological and growth disorders, cardiovascular diseases and infertility. Merck also offers a wide range of well-known brands for consumer and preventive health care. The Chemicals business sector offers chemicals for sophisticated applications: liquid crystals for displays, effect pigments for industry and cosmetics, analytical reagents and test kits, as well as products and services along the entire process chain of the pharmaceutical and biotech industry.Merck's success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
Chart:
| Last Price
|
29.91
|
| Price Chg.
|
0.00
|
| Price Chg. %
|
0.00%
|
| Open Price
|
29.84
|
| High Price
|
30.19
|
| Low Price
|
29.84
|
| 52w High Price
|
37.97
|
| 52w Low Price
|
25.80
|
| Volume
|
1,398
|
| 30d Avg. Volume
|
3,109
|
* Quotes delayed 20 minutes.
| Products Manufactured/Services Performed Details |
|
Healthcare
|
|
Biopharmaceuticals
|
|
Immunology
|
|
Autoimmune Disorders
|
|
Multiple Sclerosis (MS)
|
|
Adenosine Deaminase Inhibitors
|
|
Neurology
|
|
Neuromuscular Disorders
|
|
Multiple Sclerosis (MS)
|
|
Adenosine Deaminase Inhibitors
|
| Period Length/End
|
| Total Revenue
|
|
Gross Margin %
|
|
Operating Income
|
|
Operating Margin %
|
| Tax Rate %
|
| Income After Taxes
|
| Net Income Margin %
|
|
F.D. EPS - Incl. Xord. Items
|
| Book Value Per Share
|
Ratios
|
P/R Ratio (TTM)
|
n/a
|
|
P/E Ratio (TTM)
|
n/a
|
| Price To Free Cash Flow (TTM)
|
n/a
|
| Price To Book Value
|
n/a
|
| Net Assets to Market Cap. %
|
n/a
|
| Beta
|
n/a
|
|
Days to Sell Inventory
|
n/a
|
|
Current Ratio
|
n/a
|
|
Quick Ratio
|
n/a
|
| Interest Coverage
|
n/a
|
| Debt to Market Cap. %
|
n/a
|
| Return on Equity %
|
n/a
|
| Return on Assets %
|
n/a
|
| Return on Invested Capital %
|
n/a
|
|
Name |
Trailing Revenue |
P/R Ratio (TTM) |
P/E Ratio (TTM) |
1 Year Return % |
Overlap |
| Average |
|
|
|
|
|
Notes:
- The company operates in the pharmaceutical and chemical industries. Healthcare products include branded prescription drugs, e.g. for the treatment of cancer, neurological and growth disorders, cardiovascular diseases and infertility. Chemical products include performance materials including coatings and materials for OLEDs. They did not disclose any specific competitors for the fiscal period ending December 31, 2010.
|
Name |
Last Quarter Financial Stats |
1 YR Price Performance % |
|
Y/Y Revenue Growth % |
Sequential Revenue Growth % |
Y/Y Margin Growth % |
Sequential Margin Growth % |
Astellas Pharma Inc.
|
n/a
|
n/a
|
n/a
|
n/a
|
12.69%
|
|
Forest Laboratories, Inc.
|
7.97
|
1.20
|
91.44
|
-16.31
|
18.22%
|
|
Mitsubishi Tanabe Pharma Corp
|
n/a
|
n/a
|
n/a
|
n/a
|
n/a
|
|
Nippon Shinyaku Co., Ltd.
|
n/a
|
n/a
|
n/a
|
n/a
|
1.63%
|
|
SRD Pharmaceuticals, Inc.
|
n/a
|
n/a
|
n/a
|
n/a
|
n/a
|
|
SUMITOMO CHEMICAL CO LTD
|
n/a
|
n/a
|
n/a
|
n/a
|
-2.67%
|
|
Sanofi SA (ADR)
|
0.60
|
3.14
|
-49.49
|
-24.62
|
17.92%
|
|
Tioga Pharmaceuticals, Inc.
|
n/a
|
n/a
|
n/a
|
n/a
|
n/a
|
| Average |
4.28
|
2.17
|
20.98
|
-20.47
|
9.56%
|
Notes:
- The company has products in the pharmaceutical and and chemical industries. They do not disclose revenues derived from any specific customer for the fiscal period December 31, 2010.
|
Name |
Subtypes |
1 YR Price Performance % |
|
Ablynx NV
|
Research Collaboration
|
28.80%
|
|
Ambrx, Inc
|
In-licensing, Research Collaboration
|
n/a
|
|
Apitope International NV
|
Research Collaboration
|
n/a
|
|
Applied Materials, Inc.
|
Research Collaboration
|
-4.75%
|
|
Astellas Pharma Inc.
|
Marketing, Out-licensing
|
12.69%
|
|
BioMarin Pharmaceutical Inc.
|
Research Collaboration
|
29.44%
|
|
Bristol Myers Squibb Co.
|
In-licensing
|
6.98%
|
|
Cardiff University
|
Research Collaboration
|
n/a
|
|
Eli Lilly & Co.
|
Research Collaboration
|
2.13%
|
|
Flamel Technologies S.A. (ADR)
|
Research Collaboration
|
-39.69%
|
|
Forest Laboratories, Inc.
|
Out-licensing
|
18.22%
|
|
Government - Germany
|
Research Collaboration
|
n/a
|
|
Idera Pharmaceuticals, Inc.
|
In-licensing
|
-50.29%
|
|
Mitsubishi Tanabe Pharma Corp
|
Out-licensing
|
n/a
|
|
Newron Pharmaceuticals S.p.A
|
In-licensing, Research Collaboration
|
13.09%
|
|
Nippon Shinyaku Co., Ltd.
|
Marketing, Out-licensing
|
1.63%
|
|
Oncothyreon Inc.
|
In-licensing
|
100.00%
|
|
Otsuka Holdings KK
|
In-licensing
|
n/a
|
|
SRD Pharmaceuticals, Inc.
|
Out-licensing
|
n/a
|
|
SUMITOMO CHEMICAL CO LTD
|
Out-licensing
|
-2.67%
|
|
Sanofi SA (ADR)
|
Research Collaboration
|
17.92%
|
|
Theratechnologies Inc.
|
In-licensing
|
n/a
|
|
Tioga Pharmaceuticals, Inc.
|
Out-licensing
|
n/a
|
|
University of Texas MD Anderson Cancer Center
|
Research Collaboration
|
n/a
|
